1592U89
From Health Encyclopedia
[edit]
Facts (generated by robot; please edit if you find it inaccurate)
- The most important feature of 1592U89 is that it is new and therefore it may play a critical role for people who cannot find two new drugs needed for optimal results when starting a new combination.
- For this reason, 1592U89 is also being studied in HIV-infected persons with dementia as a means to reverse or prevent further brain damage by HIV.
- Burroughs-Wellcome's 1592U89 1592U89 is a potential HIV treatment now in early clinical trials.
- Thus, 1592U89 is phosphorylated by adenosine phosphotransferase to 1592U89-MP, which is converted by a novel cytosolic enzyme to CBV-MP.
- 1592U89 is a nucleoside analogue reverse transcriptase inhibitor and 141W94/VX-478 is an HIV protease inhibitor, designed by Vertex Pharmaceuticals.
Would you like to discuss or post question about 1592U89 ? Click here !